SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical practitioners to use and understand genomic information about prostate cancer and how it can impact their clinical practice. It offers physicians the opportunity to explore Decipher clinical data on interactive graphs, engage in hands-on exploration of clinical use scenarios and learn more about the Decipher Prostate Cancer Classifier for post-operative patient care.
The first version of the free application is an educational tool that provides physicians the opportunity to explore representative patient cases modeled from real Decipher results against published clinical validation data on an interactive graph. Users may choose different variables to compare to sample Decipher results. Users may also explore the clinical utility of the Decipher test by comparing treatment recommendations to those of physicians who participated in published Decipher clinical utility studies.
Updates to the app will be designed to allow physicians to order and receive Decipher test results directly from the application and to obtain updates on the status of each Decipher test order. In addition, physicians will be able to securely compare the data generated on their patients to published clinical validation studies.
"We believe that merging genomic data with mobile technology will transform how doctors manage patient care in the clinic," said Doug Dolginow, M.D. CEO of GenomeDx. "We designed this app so that physicians can explore case studies just as they would review a case they were treating and easily visualize how a test like Decipher can help them understand the genomic risk of their patients developing metastatic prostate cancer."
GenomeDx Biosciences will be offering a viewing of the app at AUA 2014 in booth #1775.
The Decipher Portal Professional app adds to GenomeDx's existing portfolio of mobile apps, which includes the UroSketch 3DTM series for urology patient consultations and is available for free download. Learn more at: www.deciphertest.com/DecipherPortal
The Decipher® Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Decipher continues to demonstrate that it can accurately predict aggressive disease and help physicians make treatment decisions for men with prostate cancer.
Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians and as a part of GenomeDx's ongoing program of clinical studies. To learn more about ordering the Decipher test please visit www.deciphertest.com.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com.
SOURCE GenomeDx Biosciences